DS
IMRX icon

David Shaw’s Immuneering IMRX Stock Holding History

David Shaw’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.02M Buy
+203,663
New +$1.03M ﹤0.01% 3740
2022
Q2 		– Sell
-70,127
Closed -$454K – 5527
2022
Q1 		$454K Buy
+70,127
New +$674K ﹤0.01% 4428

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

David Shaw's IMRX Position: Q2 2026 in Review

David Shaw opened a new position in Immuneering (IMRX) in Q2 2026: 203,663 shares worth $1.02M. The stake represents ﹤0.01% of the portfolio and ranks #3740 among its holdings. This is a return to the name: David Shaw previously reported a position in IMRX as recently as Q1 2022.

David Shaw first reported a position in IMRX in Q1 2022 and has held it in 2 quarters since. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • David Shaw held 203,663 shares of Immuneering worth $1.02M as of Q2 2026.
  • Immuneering was a new David Shaw position in Q2 2026.
  • Immuneering made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3740 holding.
  • David Shaw first reported a position in Immuneering in Q1 2022 and has held it in 2 quarters since.
  • 111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.